(Q35638059)

9 August 2017

1 reference

title

Direct thrombin inhibitors for anticoagulation (English)

1 reference

9 August 2017

1 reference

Edith A Nutescu

1

1 reference

9 August 2017

Ann K Wittkowsky

series ordinal

2

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

Annals of Pharmacotherapy

9 August 2017

published in

1 reference

9 August 2017

volume

38

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

99-109

1 reference

Thrombin signalling and protease-activated receptors

9 August 2017

cites work

1 reference

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

Managing oral anticoagulant therapy

21 January 2018

1 reference

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

21 January 2018

1 reference

Hemorrhagic complications of anticoagulant treatment

21 January 2018

1 reference

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

21 January 2018

1 reference

Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent

21 January 2018

1 reference

A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement

21 January 2018

1 reference

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery

21 January 2018

1 reference

In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets

21 January 2018

1 reference

Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies

21 January 2018

1 reference

21 January 2018

1 reference

The design of competitive, small-molecule inhibitors of coagulation factor Xa.

21 January 2018

1 reference

Discovery of the factor Xa inhibitor, ZK 807834 (CI-1031).

21 January 2018

1 reference

The design and synthesis of noncovalent factor Xa inhibitors

21 January 2018

1 reference

Direct thrombin inhibitors in cardiovascular medicine

21 January 2018

1 reference

Kinetics of the inhibition of thrombin by hirudin.

21 January 2018

1 reference

Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data

21 January 2018

1 reference

Recombinant hirudin in clinical practice: focus on lepirudin.

21 January 2018

1 reference

A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement

21 January 2018

1 reference

Bivalirudin: a new generation antithrombotic drug

21 January 2018

1 reference

Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial

21 January 2018

1 reference

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial

21 January 2018

1 reference

Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor

21 January 2018

1 reference

Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia

21 January 2018

1 reference

Results from late-breaking clinical trials sessions at ACC '98. American College of Cardiology

21 January 2018

1 reference

Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.

21 January 2018

1 reference

Antithrombotic therapy after prosthetic cardiac valve implantation: potential novel antithrombotic therapies.

21 January 2018

1 reference

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects

21 January 2018

1 reference

Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis

21 January 2018

1 reference

Advances in the development of thrombin inhibitors

21 January 2018

1 reference

Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study

21 January 2018

1 reference

A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.

21 January 2018

1 reference

Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial

21 January 2018

1 reference

Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1D066

1 reference

9 August 2017

1 reference